Excessive drug costs could invite price caps: AHIP's Ignagni ModernHealthcare.com But the discussion was dominated by the pioneering hepatitis C virus (HCV) drug that's vexing insurers, Medicaid and Medicare officials, and patients diagnosed with the chronic liver disease. Sovaldi has proven remarkably effective in combating the ... |
